Ureteral Stent Discomfort
Conditions
Brief summary
To assess the impact of alfuzosin vs. placebo on ureteral stent discomfort, urinary symptoms and quality of life.
Interventions
Sponsors
University of Minnesota
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>18 * Undergoing unilateral retrograde ureteroscopy with ureteral stent placement
Exclusion criteria
* Significant ureteral trauma * Concomitant ESWL or other secondary surgical procedure than may impact patient comfort * Subject with know hypersensitivity to alfuzosin hydrochloride or any component of alfuzosin hydrochloride tablets. * Pregnancy, nursing mother, or woman of child-bearing age unwilling to take contraception for the duration of the study * Undergoing bilateral ureteral stenting * Undergoing antegrade ureteral stenting * Undergoing simultaneous extracorporeal shockwave lithotripsy * Urinary infection (fever \>101, positive urine culture, many bacteria on urinalysis) * Primary bladder dysfunction that would impact ability to void without a catheter * Neurologic dysfunction that would impair pain sensation * History of chronic pain or substance abuse * Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased * Other alpha-blockers * Phosphodiesterase type 5 inhibitors for erectile function Any subject for whom the principal investigator feels it would not be in his or her best interest to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effect of study medication on urinary symptoms and quality of life | — |
| usage of analgesics/narcotics | — |
Countries
United States
Outcome results
None listed